Clinical Trial Update: A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) [Phase 2]

View source ↗

Summary

An ongoing Phase 2 clinical trial by the University of Utah is evaluating a phosphodiesterase-5 inhibitor for neonatal congenital diaphragmatic hernia with pulm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Diaphragmatic Hernia
• Pulmonary Hypertension

Drugs mentioned

• Phosphodiesterase-5 inhibitor

Snippet

Sponsor: University of Utah | Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypertension | Phase 2 | Status: RECRUITING